Adaptive Trials Growing Among CROs, Pharma
June 5, 2013 | Adaptive trials continue to gain ground, says Ken Getz, Director of the Tufts Center for the Study of Drug Development. He says the industry as a whole is seeing an adoption rate of about 20%, with regulators receptive to even broader implementation. Outsourcing Pharma
Click here to log in.
Text Only 2000 character limit
Page 1 of 1